cbdMD (YCBD) Stock Price, News & Analysis

Company Overview

cbdMD, Inc. (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities. Third-party laboratory testing is conducted on every batch to verify potency and ensure products are free of THC or within federally approved limits. cbdMD markets both broad-spectrum and isolate-based formulations, targeting consumers seeking natural alternatives for stress relief, sleep support, and post-exercise recovery.

cbdMD’s distribution network spans e-commerce, major online marketplaces, and brick-and-mortar retailers across the United States, with expanding presence in select international markets. The company partners with pharmacies, specialty wellness stores, and veterinarians to broaden its retail footprint, while its direct-to-consumer website serves as a primary channel for product innovation feedback and subscription services.

Since its listing on the NYSE American exchange, cbdMD has pursued strategic product line extensions and marketing collaborations to drive brand awareness. The company emphasizes quality assurance, regulatory compliance, and ongoing research to support the evolving cannabinoid market and to meet consumer demand for trusted CBD solutions.

Key Stats

• Today's Range: $0.73 to $0.77
• 50-Day Range: $0.65 to $1.01
• 52-Week Range: $0.47 to $2.56
• Volume: 122,511 shs
• Average Volume: 655,484 shs
• Market Capitalization: $7.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Buy

cbdMD Stock Analysis - MarketRank™

cbdMD scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

cbdMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

cbdMD has a consensus price target of $2.00, representing about 162.8% upside from its current price of $0.76.

Amount of Analyst Coverage

cbdMD has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

cbdMD has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.49% of the float of cbdMD has been sold short.

Short Interest Ratio / Days to Cover

cbdMD has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in cbdMD has recently increased by 188.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

cbdMD does not currently pay a dividend.

Dividend Growth

cbdMD does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: -0.68

News Sentiment

cbdMD has a news sentiment score of -0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for cbdMD this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, cbdMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.50% of the stock of cbdMD is held by insiders.

Percentage Held by Institutions

7.18% of the stock of cbdMD is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/25/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Business Services
• Industry: ADVERTISING/MKTG SVCS
• Sub-Industry: Consumer Goods
• Current Symbol: NYSEAMERICAN:YCBD
• CIK: 1644903
• Web: www.cbdmd.com
• Phone: (704) 445-3060
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for cbdMD: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +162.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.04 million
• Net Margins: -13.29%
• Pretax Margin: -13.29%
• Return on Equity: -33.60%
• Return on Assets: -23.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.82
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $19.19 million
• Price / Sales: 0.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 10,500,000
• Free Float: 9,816,000
• Market Cap: $7.99 million
• Optionable: Not Optionable
• Beta: 2.16